Phosphatidylinositol 3-kinase (PI3K) promotes cancer cell survival, migration, growth and proliferation by generating phosphatidylinositol 3,4,5-trisphosphate (PIP 3 ) in the inner leaflet of the plasma membrane. PIP 3 recruits pleckstrin homology domain-containing proteins to the membrane to activate oncogenic signaling cascades. Anticancer therapeutics targeting the PI3K/AKT/mTOR (mammalian target of rapamycin) pathway are in clinical development. In a mass spectrometric screen to identify PIP 3 -regulated proteins in breast cancer cells, levels of the Rac activator PIP 3 -dependent Rac exchange factor-1 (P-REX1) increased in response to PI3K inhibition, and decreased upon loss of the PI3K antagonist phosphatase and tensin homolog (PTEN). P-REX1 mRNA and protein levels were positively correlated with ER expression, and inversely correlated with PI3K pathway activation in breast tumors as assessed by gene expression and phosphoproteomic analyses. P-REX1 increased activation of Rac1, PI3K/AKT and MEK/ERK signaling in a PTEN-independent manner, and promoted cell and tumor viability. Loss of P-REX1 or inhibition of Rac suppressed PI3K/AKT and MEK/ERK, and decreased viability. P-REX1 also promoted insulin-like growth factor-1 receptor activation, suggesting that P-REX1 provides positive feedback to activators upstream of PI3K. In support of a model where PIP 3 -driven P-REX1 promotes both PI3K/AKT and MEK/ERK signaling, high levels of P-REX1 mRNA (but not phospho-AKT or a transcriptomic signature of PI3K activation) were predictive of sensitivity to PI3K inhibitors among breast cancer cell lines. P-REX1 expression was highest in estrogen receptor-positive breast tumors compared with many other cancer subtypes, suggesting that neutralizing the P-REX1/Rac axis may provide a novel therapeutic approach to selectively abrogate oncogenic signaling in breast cancer cells.
INTRODUCTION
The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) pathway is the most commonly aberrantly activated pathway in human cancer, promoting cell growth, migration, survival and proliferation. Genes encoding proteins in this pathway are mutated in 470% of breast cancers, and pathway activation has been linked with resistance to antiestrogen and anti-HER2 therapies in estrogen receptor α-positive (ER+) and HER2-positive breast cancers, respectively. 1 PI3K pathway-targeted therapeutics are in clinical development. Class IA PI3Ks are activated by receptor tyrosine kinases such as members of the epidermal growth factor receptor family (EGFR, HER3) and the insulin receptor family (InsR, insulin-like growth factor-1 (IGF-1) receptor, IGF-1R), as well as by Gβγ subunits released from activated G-protein-coupled receptors (GPCRs). 2 PI3K phosphorylates phosphatidylinositol (4,5)-bisphosphate in the inner leaflet of the plasma membrane to yield phosphatidylinositol (3,4,5)-trisphosphate (PIP 3 ). 3 Lipid phosphatase activity of the tumor suppressor phosphatase and tensin homolog (PTEN) antagonizes PI3K by dephosphorylating PIP 3 . 4 PIP 3 recruits AKT and other pleckstrin homology (PH) domain-containing proteins to the membrane to promote their interaction and initiate signaling cascades.
In a proteomic screen to identify PIP 3 -regulated proteins as effectors and markers of PI3K activation in breast cancer cells, we found that the levels of PIP 3 -dependent Rac exchange factor-1 (P-REX1) were inversely correlated with PI3K activation. This association was confirmed in human breast tumors. P-REX1 was most highly expressed in estrogen receptor-positive (ER+) breast cancer compared with various other cancer subtypes, and P-REX1 mRNA levels were predictive of sensitivity to PI3K inhibition. We also found that P-REX1 activates IGF-1R/InsR, Rac1, PI3K/AKT and MEK/ERK signaling, and promotes cell and tumor viability. These findings place P-REX1 both downstream and upstream of PI3K, suggesting that P-REX1 is a key component of a positive feedback loop that drives oncogenic signaling. 1 
RESULTS

PI3K activity regulates P-REX1 expression
We performed a mass spectrometry (MS)-based proteomic screen to identify proteins modulated by PI3K pathway activity in breast cancer cells. MCF-7 cells stably expressing short hairpin RNA targeting PTEN (shPTEN) or short hairpin mismatch control (shMM) were treated with or without the pan-PI3K inhibitor BKM-120 5 for 16 h. Lysates were analyzed by multidimensional protein identification technology coupled with tandem mass spectrometry. Proteins exhibiting altered abundance in response to PI3K inhibition and/or PTEN knockdown are listed in Supplementary Table S1 . Comparing the lists of proteins altered ⩾ 1.5-fold in abundance, we identified P-REX1 as a protein downregulated by PTEN knockdown (which activates PI3K) and upregulated by PI3K inhibition (Figures 1a and b) . P-REX1 is a guanine exchange factor (GEF) that integrates inputs from GPCRs via Gβγ, and from receptor tyrosine kinases and GPCRs via PIP 3 to activate the Rho family GTPases Rac1/2/3. 6 Given that P-REX1 was previously implicated in prostate cancer metastasis 7 and shown to promote oncogenic signaling, 8, 9 we further investigated its role in PI3K signaling in breast cancer.
We validated MS results by immunoblotting of lysates from breast cancer cells treated with inhibitors of PI3K or AKT. MCF-7/ shMM and T47D/shMM cells treated with 1 μM BKM-120 showed reduced p-AKT and increased P-REX1 protein levels over time (Figures 1c and d) . The reason that P-REX1 levels did not increase as markedly in shPTEN cells compared with shMM cells upon PI3K inhibition is unclear but may be due in part to residual PIP 3 in shPTEN cells, as evidenced by residual p-AKT in BKM-120-treated T47D/shPTEN cells ( Figure 1d ). As the P-REX1 homolog P-REX2a was found to bind PTEN, 10 we considered that PTEN may bind and stabilize P-REX1. However, we detected only very low levels of P-REX1/PTEN interaction in cells (data not shown). Treatment with the pan-PI3K inhibitor GDC-0941 11 similarly increased P-REX1 levels in parental MCF-7 and T47D cells, whereas AKT inhibition with MK-2206 did not (Figure 1e ). Thus, P-REX1 levels are modulated downstream of PI3K, but independently of AKT.
We also explored whether PI3K activity modulates P-REX1 gene expression. PI3K inhibition for 4 or 24 h increased P-REX1 mRNA levels in MCF-7 cells (Supplementary Figures S1A and B) . Mining of prior gene expression microarray data from isogenic MCF-7/ shPTEN, T47D/shPTEN and MDA-MB-361/shPTEN cells compared with respective shMM controls 12 revealed that P-REX1 mRNA levels were significantly downregulated in all shPTEN lines. In addition, PI3K inhibition increased P-REX1 protein levels in cells pre-treated with the translation inhibitor cycloheximide (Supplementary Figure S1C) . These data suggest that P-REX1 levels are modulated by PI3K signaling at the transcriptional and posttranslational levels: PIP 3 -mediated activation of P-REX1 may induce P-REX1 protein turnover as a form of negative feedback, and PI3K inhibition blocks negative feedback to induce transcription of genes encoding proteins that activate and transduce PI3K signaling (for example, ERBB3, IGF-1R, 13 TSC1 14 and PREX1).
Tumor levels of P-REX1 are inversely correlated with PI3K/AKT/ mTOR pathway activation, and positively correlated with ER expression in breast tumors As PI3K activity modulates P-REX1 levels in breast cancer cells, we explored this relationship in human tumors. Using reverse-phase protein array analysis of lysates from 712 primary breast tumors, we measured levels of P-REX1, phosphoprotein markers of PI3K pathway activation (p-AKTT308, p-AKTS473, p-4E-BP1T37/46, p-4E-BP1S65, p-p70S6KT389, p-mTORS2448, p-TSC2T1462, p-GSK3α/βS21/9), ER and HER2. P-REX1 expression was inversely correlated with all PI3K pathway markers, positively correlated with ER levels and modestly negatively correlated with HER2 levels (Supplementary Figure S2) . Hierarchical clustering of P-REX1 and phosphoprotein data revealed (1) two (phospho)protein clusters, where P-REX1 clustered independently from PI3K pathway markers, and (2) several tumor clusters, where the two most distinct clusters exhibited high P-REX1 with low PI3K activation, and low P-REX1 with high PI3K activation (Figure 2a) . We then evaluated patterns of P-REX1 gene expression in human tumors. P-REX1 mRNA and protein levels were well correlated (r 2 = 0.6, P o 0.0001)) in a set of 667 breast tumors (Supplementary Figure S3A) . P-REX1 mRNA and protein levels were inversely correlated with a PI3K activation score derived from an expression signature of 1793 genes (Supplementary Table S2 , derived from Creighton et al.;
15 signature does not include P-REX1) across 1950 solid tumors and 919 breast tumors from The Cancer Genome Atlas (TCGA; Figure 2b and Supplementary Figure S3B) , and within two other data sets of 420 and 553 breast tumors 16 ( Supplementary Figures S3C and D) . In a fourth data set of 100 breast tumors, 17 P-REX1 mRNA levels were lower in tumors exhibiting a gene expression signature of PTEN-loss compared with 'PTEN-intact' tumors ( Figure 2c ). These findings validate our observations in breast cancer cells (Figure 1 and Supplementary Figure S1 ), and confirm that P-REX1 levels are inversely correlated with PI3K activity.
Stratifying breast tumors by clinical ER status or molecular subtype, we found that P-REX1 protein and mRNA levels were significantly higher in ER+/luminal tumors compared with ER − / basal tumors, and compared with a diversity of other tumor subtypes (Figure 2d and Supplementary Figures S3E and J). P-REX1 and ER mRNA levels were strongly correlated in breast tumors (Figure 2e ). These observations suggest that P-REX1 may be an ER+ breast tumor-specific protein.
Genetic lesions in PREX1 are enriched in cancers with mutations in the PI3K pathway Coexistent mutations in genes encoding proteins that lie in the same signaling cascade (for example, HER2 and PIK3CA 18 ) are thought to provide robustness to promote oncogenic phenotypes and fitness. 19 We analyzed genomic data sets to determine whether PREX1 is genetically altered in human tumors and whether PREX1 lesions coexist with other PI3K pathway alterations. PREX1 is amplified or mutated in 3.65% (163/4462) of cancers and in 3.65% (25/685) of primary breast tumors (Supplementary Table  S3 ). PREX1 gene copy number significantly correlates with P-REX1 mRNA and protein levels in breast tumors (Supplementary Figures S3K and L), suggesting that PREX1 amplification confers increased expression. We then compared the genetic status of PREX1 and 79 PI3K pathway-related genes across 1523 solid tumors (482 breast, 212 colorectal, 143 glioblastoma, 179 lung, 207 ovarian, 93 prostate and 207 sarcoma). PREX1 lesions significantly co-occurred with lesions in 51 of 79 PI3K pathway-related genes (Fisher's exact test P o0.05; Supplementary Table S4) ; however, PREX1 lesions were not significantly enriched in tumors with lesions in PIK3CA or PTEN. These results suggest that PREX1 alterations may be enriched in PI3K pathway-driven tumors to enhance PI3K pathway robustness, and/or vice versa.
P-REX1 activates IGF-1R/InsR, PI3K/AKT and MEK/ERK signaling As PIP 3 activates P-REX1 6 and PI3K inhibition increases P-REX1 levels ( Figure 1 and Supplementary Figure S1 ), we hypothesized that P-REX1 levels are regulated by negative feedback signaling from PI3K. To determine whether P-REX1 provides feedback to PI3K to form a complete circuit, we overexpressed exogenous myc-PREX1-HA or knocked down endogenous P-REX1 using RNA interference in MCF-7 and T47D cells. P-REX1 overexpression increased AKT phosphorylation compared with control under IGF-1-stimulated and heregulin (HRG, HER3 ligand)-stimulated conditions (Figures 3a and b) . Conversely, P-REX1 knockdown decreased growth factor-induced and steady-state p-AKT in MCF-7 cells (Figure 3a ). These effects were confirmed using a second small interfering RNA (siRNA) against the 3′-untranslated region of P-REX1 (siPREX1-2), and restoration of P-REX1 expression using the myc-PREX1-HA cDNA construct (not targeted by siPREX1-2) rescued p-AKT levels ( Figure 3c ).
As P-REX2a directly inhibits PTEN lipid phosphatase activity to increase PIP 3 levels, 10 we also evaluated P-REX1 effects in intrinsically PTEN-deficient breast cancer cells. P-REX1 overexpression in ZR75-1 and MDA-MB-415 cells increased p-AKT, whereas P-REX1 knockdown reduced p-AKT in ZR75-1 cells (Figures 3d-f ; note: as ZR75-1 cells express high levels of endogenous P-REX1, the levels of myc-PREX1-HA overexpression are modest). Thus, the effects of P-REX1 on AKT activation are PTEN-independent. In contrast to reported effects of P-REX2a, 10 we did not detect an effect of P-REX1 on PTEN lipid phosphatase activity (data not shown).
As P-REX1 activates the PI3K/AKT pathway (Figures 3a-f ) that can crosstalk with Rac/Pak/Raf/MEK/ERK pathways, 20 and P-REX1 GEF function activates Rac1/2/3 6,9 that promote Pak/Raf/MEK/ERK activation, [21] [22] [23] [24] we tested whether P-REX1 also modulates MEK/ ERK signaling in breast cancer. Transfected MCF-7 and T47D cells were serum-starved, and then stimulated with IGF-1 or HRG. P-REX1 overexpression increased and knockdown decreased basal and growth factor-induced p-MEK (Figures 3a and b) . Similar effects on p-MEK and p-ERK were observed under steady-state conditions in MDA-MB-415 and ZR75-1 cells (Figures 3d-f) .
We observed that P-REX1 knockdown in MCF-7 and T47D cells reduced levels of p-IGF-1Rβ/p-InsRβ (Figure 3a) . To determine whether P-REX1 effects on IGF-1R/InsR activation were PI3K-dependent, we knocked down P-REX1 expression in MCF-7 cells, pre-treated with or without GDC-0941 (to inhibit PI3K), and then stimulated with or without IGF-1. While P-REX1 knockdown reduced p-IGF-1Rβ/p-InsRβ and increased total IGF-1Rβ, PI3K inhibition had no effect on receptor phosphorylation but decreased p-AKT (Figure 3g ). This suggests that P-REX1 promotes IGF-1Rβ/InsRβ activation independently of PI3K/AKT activity. P-REX1 promotes PI3K/AKT and MEK/ERK signaling via Rac activation As P-REX1 activates Rac1/2/3, 6,9 which can promote Pak/Raf/MEK/ ERK activation, [21] [22] [23] [24] and Rac1 was recently found to activate the p110β isoform of Class IA PI3K, 25, 26 we postulated that P-REX1 acts through Rac to drive the activation of both PI3K/AKT and MEK/ERK signaling in ER+ breast cancer cells. We first assessed the role of P-REX1 in Rac1 activation in T47D cells with or without RNAiinduced P-REX1 knockdown. In an activated Rac1 pull-down assay, cell lysates treated with GDP (to inactivate Rac1) or GTPγS (nonhydrolyzable GTP, to activate Rac1) were used as negative and positive controls, respectively. Immunoblot analysis of pull-down eluates showed that the levels of activated Rac1 were lower in GDP-treated than in GTPγS-treated lysates, confirming assay specificity for activated (GTP-bound) Rac1 (Supplementary Figure  S4A) . Surprisingly, synthetic Rac1 activation with GTPγS increased P-REX1/Rac1 interaction compared with synthetic Rac1 inactivation with GDP, suggesting that P-REX1 preferentially interacts with activated Rac1. P-REX1 knockdown decreased activated Rac1, which was found in complex with p-ERK. As Rac1 has been found in a triple complex with Pak1 and MEK1/2, 21 the MEK1/2 substrates ERK1/2 could also be part of this complex. These findings confirm that P-REX1 activates Rac1 in ER+ breast cancer cells, and loss of P-REX1-induced Rac1 activation decreases p-ERK1/2.
We then tested whether Rac signaling is required for the activation of PI3K/AKT and MEK/ERK. Treatment with the Rac1/2/3 small-molecule inhibitor EHT1864 27 Figure S4B) . These results suggest that Rac GTPases drive activation of the PI3K/AKT and MEK/ERK pathways in ER+ breast cancer cells harboring genetic lesions in the PI3K pathway. As P-REX1 activates Rac, these findings place P-REX1/Rac upstream of these signaling cascades.
To confirm the involvement of Rac activation in P-REX1-induced oncogenic signaling, we tested the effects of Rac inhibition with EHT1864 on cells overexpressing myc-PREX1-HA or control. While P-REX1 overexpression increased p-MEK, p-ERK and p-AKT, such effects were abrogated by treatment with EHT1864 (Figures 4e-h) . Interestingly, Rac inhibition increased levels of endogenous P-REX1 (Figure 4e ), suggesting that Rac signaling provides negative feedback to control P-REX1 levels. P-REX1 promotes viability of breast cancer cells and tumors As P-REX1 increases oncogenic signaling, we tested whether P-REX1 also promotes cell viability. Cells transfected with siRNA against P-REX1, vectors encoding myc-PREX1-HA or controls were assayed using XTT assay, which measures mitochondrial enzymatic activity. P-REX1 overexpression in T47D, MCF-7 and MDA-MB-415 cells increased viable cell number, whereas P-REX1 knockdown decreased viability in T47D cells (Figures 5a-d) . Similarly, inhibition of Rac with EHT1864 decreased viability in all lines tested (Figures 5a-e) . In agreement with prior findings, 8 knockdown of P-REX1 also decreased MCF-7 xenograft growth in immunodeficient mice (Figure 5f and Supplementary Figure S5) . P-REX1 contains amino-terminal tandem DH/PH domains characteristic of GEFs (Supplementary Figure S6A) . The DH domain is required for binding Gβγ and GEF activity. The PH domain is needed for PIP 3 binding and intracellular membrane localization. 28 Prior evidence indicates that PH domain binding to PIP 3 may increase GTPase (that is, Rac)-binding activity of the DH domain in GEFs, although this remains controversial and may differ between GEFs (reviewed in Hoffman and Cerione 29 ). Adding to this understanding, we observed that deletion of the DH domain (ΔDH) increases P-REX1 binding to PIP 3 , and facilitates interaction with other phosphatidylinositol species (Supplementary Figures S6B and C) , suggesting that the DH domain regulates interactions of the PH domain with lipid membranes. Adjacent to the DH/PH domains are two disheveled, Egl-10 and pleckstrin domains reported to be required for interaction with mTOR; 30 however, we did not detect an interaction of P-REX1 with mTOR in immunoprecipitation experiments (data not shown). Overexpression in T47D cells revealed that full-length P-REX1 increased viability, whereas the ΔDH and ΔDH/PH mutants were less effective (Supplementary Figure S6D) . These findings suggest that P-REX1 GEF activity and membrane localization are critical for P-REX1-mediated promotion of cell viability.
As P-REX1 requires PIP 3 for activation, 6 P-REX1 promotes PI3K/ AKT and MEK/ERK signaling (Figure 3) , and combined inhibition of PI3K and MEK has strong antitumor effects (reviewed in Saini et al. 20 ), we hypothesized that P-REX1-expressing cells would be sensitized to pharmacologic inhibition of PI3K. Breast cancer cell lines (n = 43) were dichotomized based on P-REX1 mRNA levels (extracted from the Cancer Cell Line Encyclopedia 31 ) and IC 50 (half-maximal inhibitory concentration) values in response to GDC-0941 and the PI3K/mTOR dual inhibitor PI-103 (IC 50 values extracted from O'Brien et al. 32 ) were compared between P-REX1-high vs -low cell lines. P-REX1-high cells were significantly more sensitive to GDC-0941 (P = 0.01), and showed a trend towards sensitivity to PI-103 (P = 0.07) compared with P-REX1-low cells (Figure 5g ). In agreement with P-REX1 levels being highest in ER+ breast cancers (Figures 2d-e and Supplementary Figure S3 ), P-REX1-high cells classified mainly as luminal or HER2-enriched by molecular subtyping, whereas P-REX1-low cells were mostly basalor normal-like. In a multivariate model including molecular subtype, P-REX1 status (high/low) was not independently predictive of sensitivity to PI3K inhibition, suggesting that P-REX1 expression is tightly linked with molecular subtype. Transcriptomic PI3K activation score and P-AKT T308 levels were not predictive of sensitivity to PI3K inhibition (Supplementary Figure S7) .
DISCUSSION
Herein, we globally identified proteins quantitatively modulated by PI3K pathway inhibition and activation in breast cancer cells. We found that P-REX1 levels are inversely correlated with PI3K activation and positively correlated with ER expression in human breast tumors. P-REX1 activates Rac GTPases to promote activation of IGF-1R/InsR, PI3K/AKT and MEK/ERK to increase breast cancer cell viability in a PI3K/PIP 3 -dependent, PTEN-independent manner. Therefore, P-REX1 lies both downstream and upstream of PI3K, and creates a positive feedback loop to drive oncogenic signaling ( Figure 6 ). In support of a model where P-REX1/Rac drives both PI3K/AKT and MEK/ERK signaling, breast cancer cells expressing high levels of P-REX1 are more sensitive to PI3K inhibition than P-REX1-low cells.
We and others found that P-REX1 knockdown reduces levels of activated Rac in breast cancer cells (Supplementary Figure S4A and Ebi et al. 33 and Sosa et al.
9
)
. In addition, we demonstrated that P-REX1 activates IGF-1R/InsR, PI3K/AKT and MEK/ERK signaling in breast cancer cells in a Rac activation-dependent manner (Figures 3-5 and Supplementary Figure S4) . Recent studies have implicated Ras and Rho family GTPases in the regulation of PI3K activity. Fritsch et al. 25 showed that activated Rac1 binds and activates PI3K/p110β to increase PIP 3 production. 26 Therefore, P-REX1 may activate PI3K/p110β via Rac in breast cancer cells. P-REX1 also promotes activation of IGF-1R/InsR in a PI3K/PIP 3 -independent, Rac-dependent manner (Figures 3g and 4g-h ), which in turn can activate PI3K/p110α. 34 We did not consistently detect P-REX1/IGF-1Rβ or P-REX1/IRS-1 interaction in immunoprecipitation trials (data not shown), and the mechanism underlying P-REX1-mediated receptor activation requires further study.
Cross-talk between the PI3K/AKT and Pak/Raf/MEK/ERK pathways exists at several levels, 20 and we demonstrated that P-REX1 modulates both pathways in ER+ breast cancer cells. P-REX1 activates MEK/ERK signaling via activation of Rac (Figure 4 and Supplementary Figure S4) . The Rac effector Pak1 can serve as an intermediary to activate Raf/MEK/ERK signaling ( Figure 6 and refs [21] [22] [23] [24] ). In support of our findings, a recent study showed that P-REX1 knockdown reduces Rac1/Pak/Raf/MEK/ERK signaling. 33 Furthermore, Rac/Pak1-mediated activation of ERK and AKT is required for HER2-induced transformation of breast cancer cells. 35 We thus infer that P-REX1 GEF activity promotes Rac/Pak-induced activation of MEK/ERK and PI3K/AKT in ER+ breast cancer cells. Additionally, we detected binding of activated Rac1 to p-ERK1/2, and synthetic Rac1 activation with GTPγS increased P-REX1/Rac1 interaction (Supplementary Figure S4A) . A Rac1/Pak1/MEK1/2 complex has been described; 21 we speculate that this complex may also bind ERK1/2. Whether P-REX1 interacts with Rac1 when complexed with Pak1/MEK1/2/ERK1/2 is unclear. Given that GEFs typically interact with GDP-bound GTPases, GAPs (GTPase-activating proteins) interact with GTP-bound GTPases, and as other GEF/GAP/Rho GTPase complexes have been described, 36 it is conceivable that P-REX1 interacts with a complex containing activated Rac1 and a GAP.
In support of a role for P-REX1 driving both the PI3K/AKT and MEK/ERK pathways, we observed that high P-REX1 mRNA levels, but not PI3K activation score (by gene expression) or P-AKT T308 level, are predictive of increased sensitivity to PI3K inhibitors (Figure 5g and Supplementary Figure S7) . Drug combinations targeting PI3K and MEK elicit marked antitumor effects in preclinical studies, but such combinations are accompanied by considerable toxicity in patients. 20 Thus, P-REX1 may be a marker of cells in which PI3K inhibitors alone will block both PI3K and MEK. Indeed, PI3K inhibition decreases P-ERK levels, which, in turn, Figure 4 . Rac promotes activation of PI3K/AKT and MEK/ERK and is required for P-REX1-induced activation of these pathways in breast cancer. (a-d) Immunoblot analysis of lysates from cells treated as indicated with or without serum-starvation for 24 h, pre-treated with or without 50 μM EHT1864 for 2 h and then stimulated with or without 20 ng/ml HRG or 100 ng/ml IGF-1. (e-h) Immunoblot analysis of lysates from cells transiently (e, g and h) or stably (f) transfected with myc-PREX1-HA or vector (Vec) control, maintained in 10% fetal bovine serum (FBS) (e-f) or serum-starved for 24 h (g,h), pre-treated with or without 50 μM EHT1864 for 2 h (e-h) and then stimulated with or without IGF-1 for 10 min (g,h). Figure 6 . Model of PI3K-dependent P-REX1-positive feedback to activate Rac, IGF-1R/InsR, PI3K/AKT and MEK/ERK signaling. Growth factor receptor tyrosine kinase (RTKs) and protein-coupled receptors (GPCRs) activate PI3K, which produces PIP 3 . P-REX1 is recruited to the membrane via PH domain binding to PIP 3 . Activation of GPCRs induces dissociation of Gβγ subunits, which bind the P-REX1 DH domain to promote its GEF activity and Rac activation. Rac activates PI3K/p110β to increase PIP 3 production, stimulates Raf/MEK signaling via Pak, interacts with p-ERK and promotes actin cytoskeleton remodeling. P-REX1 also promotes PI3K-independent activation of IGF-1R/InsR, which can lead to further activation of PI3K and MEK signaling.
induces upregulation of the proapoptotic protein Bim in P-REX1-expressing cells. 33 Interestingly, the two luminal/ER+ breast cancer cell lines most resistant to GDC-0941 (HCC-1500 and MDA-MB-134VI; Figure 5g ) harbor PAK1 amplification, and Pak1 knockdown or treatment with the Pak inhibitor PF-3758309 was shown to induce apoptosis and decrease MEK/ERK phosphorylation in these cells. 37 PAK1 is amplified in 8.4%, 13.8% and 3.7% of luminal, HER2-enriched and basal breast cancers, respectively (extracted from Cancer Genome Atlas Network 38 using cBio 39 ). Thus, P-REX1 expression and PAK1 amplification may serve as respective positive and negative biomarkers of sensitivity to PI3K inhibitors in breast cancer.
The P-REX1 homolog P-REX2a binds PTEN and inhibits its lipid phosphatase activity.
10 While we detected a low level of P-REX1/ PTEN binding in situ, in vitro and in situ analyses did not reveal an effect of P-REX1 on PTEN phosphatase activity (data not shown). Furthermore, we observed that P-REX1 activates PI3K/AKT and MEK/ERK signaling in PTEN-null cells (MDA-MB-415 and ZR75-1; Figures 3d-f and 4f ). Thus, P-REX1 and P-REX2a may promote PI3K pathway activation via different mechanisms.
In summary, we report that P-REX1 mediates a PI3K/PIP 3 -dependent positive feedback loop to promote activation of Rac, IGF-1R/InsR, PI3K/AKT and MEK/ERK signaling in ER+ breast cancer. Combined targeting of two key signaling nodes in cancer, PI3K and MEK, is being investigated in several ongoing clinical studies. 20 Thus, targeting the P-REX1/Rac axis may inhibit both PI3K and MEK signaling to elicit anticancer effects. Our mechanistic findings on P-REX1 are from ER+ breast cancer models harboring genetic lesions in the PI3K pathway; P-REX1 effects in ERBB2/PIK3CA/PTEN-wild-type ER+ models, and in ER − models remain to be determined. Furthermore, P-REX1 mRNA expression is predictive of sensitivity to PI3K inhibitors in breast cancer cells, offering P-REX1 as a biomarker to identify tumors likely to respond to these agents. P-REX1 is most highly expressed in ER+ breast cancers, suggesting that P-REX1 is an oncoprotein mainly in this subtype of cancer. As P-REX1 knockout mice are generally healthy with mild neutrophilia, 40 targeting of P-REX1 may provide a high therapeutic index in patients.
MATERIALS AND METHODS
Cell culture
Cell lines (ATCC, Manassas, VA, USA) were grown in Dulbecco's modified Eagle's medium (Life Technologies, Grand Island, NY, USA) with 10% fetal bovine serum (Hyclone, South Logan, UT, USA). MCF-7 and T47D cells stably expressing short hairpin RNA targeting PTEN or shMM were described previously. 41 Generation of other stable cell lines is described in Supplementary Methods. 
Mass spectrometry
Lysates from MCF-7/shPTEN and MCF-7/shMM cells treated with 1 μM BKM-120 or DMSO (control) for 16 h were analyzed by multidimensional protein identification technology coupled with tandem MS/MS. 42, 43 Proteins were identified using the Sequest algorithm 44 and assembled into groups using IDPicker 45 (details in Supplementary Methods).
Immunoblotting
Cells were lysed in RIPA buffer containing protease and phosphatase inhibitors. Lysates were sonicated for 15 s and centrifuged at 18 000 g for 10 min at 4°C, and the protein in supernatants was quantified using BCA assay (Pierce, Rockford, IL, USA cells (MCF-7/shPREX1 or/shNSC; described in Supplementary Methods) suspended in 50% Matrigel (BD Biosciences). Tumor diameters were measured two times per week using calipers (volume = length × width 2 /2), and volumes were analyzed as percent baseline by two-way analysis of variance followed by Bonferroni post hoc comparison.
Reverse-phase protein array analysis
Tumors analyzed by reverse-phase protein array were part of TCGA project. P-REX1 was quantified specifically for this study. Other (phospho)proteins were quantified as part of TCGA. 46 All tumor proteomic data has been deposited at The Cancer Proteome Atlas (http://app1.bioinformatics. mdanderson.org/tcpa/_design/basic/index.html). Tumor lysates were analyzed as described in Supplementary Methods.
Comparing P-REX1 gene expression with sensitivity to PI3K inhibition RMA-normalized P-REX1 mRNA expression values from cancer cell lines were obtained from the Cancer Cell Line Encyclopedia. 31 Molecular subtypes of 43 breast cancer cell lines were determined by PAM50 subtyping using R software with package 'genefu,' median-centered data and the 306 intrinsic subtype genes and centroids identified in Hu et al. 47 Cell lines were dichotomized based on high vs low P-REX1 mRNA levels, and IC 50 values in response to treatment with GDC-0941 and PI-103 (obtained from O'Brien et al. 32 ) were compared between groups by MannWhitney U-test.
